Calithera Biosciences (NASDAQ:CALA) Stock Rating Lowered by Zacks Investment Research

Zacks Investment Research downgraded shares of Calithera Biosciences (NASDAQ:CALA) from a buy rating to a hold rating in a report published on Monday, Zacks.com reports.

According to Zacks, “Calithera Biosciences, Inc. is a clinical-stage pharmaceutical company. It is focused on discovering and developing small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer. The Company’s lead product candidate includes CB-839 which is in three Phase I clinical trials for the treatment of patients with solid tumors, leukemias, lymphomas, and multiple myeloma. Calithera Biosciences, Inc. is headquartered in South San Francisco, California. “

Separately, HC Wainwright restated a buy rating and issued a $4.00 price target on shares of Calithera Biosciences in a research report on Monday, August 9th.

Shares of NASDAQ CALA opened at $2.06 on Monday. Calithera Biosciences has a 52 week low of $1.78 and a 52 week high of $6.18. The stock has a market capitalization of $152.67 million, a P/E ratio of -1.86 and a beta of 1.71. The stock’s fifty day moving average is $2.22 and its 200 day moving average is $2.18.

Calithera Biosciences (NASDAQ:CALA) last issued its quarterly earnings results on Thursday, August 5th. The biotechnology company reported ($0.19) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.24) by $0.05. The company had revenue of $3.00 million during the quarter. Research analysts anticipate that Calithera Biosciences will post -0.83 earnings per share for the current year.

Large investors have recently added to or reduced their stakes in the stock. Grimes & Company Inc. boosted its stake in shares of Calithera Biosciences by 10.7% during the second quarter. Grimes & Company Inc. now owns 111,080 shares of the biotechnology company’s stock valued at $232,000 after purchasing an additional 10,758 shares in the last quarter. Gabelli Funds LLC acquired a new stake in shares of Calithera Biosciences during the first quarter valued at about $29,000. Prudential Financial Inc. acquired a new stake in shares of Calithera Biosciences during the first quarter valued at about $30,000. SG Americas Securities LLC acquired a new stake in shares of Calithera Biosciences during the first quarter valued at about $31,000. Finally, Y Intercept Hong Kong Ltd acquired a new stake in shares of Calithera Biosciences during the second quarter valued at about $34,000. 63.29% of the stock is currently owned by institutional investors and hedge funds.

About Calithera Biosciences

Calithera Biosciences, Inc is a clinical-stage biopharmaceutical company, which focuses on discovering and developing small molecule drugs that target novel and critical metabolic pathways in tumor and cancer-fighting immune cells. It offers programs such as Pipeline, Glutaminase Inhibitor, and Arginase Inhibitor.

Featured Article: What is the Quick Ratio?

Get a free copy of the Zacks research report on Calithera Biosciences (CALA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Calithera Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calithera Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.